Moderate

Pulmonary sarcoidosis — staging & treatment

granulomatous · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Sarcoidosis is a multisystem granulomatous disease with frequent pulmonary and hilar nodal involvement. Many cases (especially Scadding stage I) remit spontaneously; treatment is reserved for progressive lung disease, major organ involvement or disabling symptoms.

Red flags

  • Syncope, arrhythmia or heart block (cardiac sarcoid)
  • New neurological deficit (neurosarcoidosis)
  • Hypercalcaemia with renal impairment
  • Progressive dyspnoea with falling DLCO (advancing fibrosis)

Assessment

Differential diagnosis

  • Tuberculosis / NTM infection
  • Lymphoma
  • Berylliosis
  • Hypersensitivity pneumonitis
  • Fungal infection
  • Metastatic malignancy / lymphangitis carcinomatosa

Investigations

  • Chest X-ray for Scadding stage (I bilateral hilar nodes; II nodes+infiltrates; III infiltrates only; IV fibrosis)
  • HRCT chest (perilymphatic nodularity, upper-zone fibrosis)
  • Spirometry, lung volumes and DLCO
  • Serum calcium, ACE, LFTs, renal function and FBC
  • Tissue biopsy (EBUS-TBNA of nodes) showing non-caseating granulomas, with exclusion of infection
  • ECG and consider cardiac MRI/PET if cardiac involvement suspected; ophthalmology review

Management

  • Establish the diagnosis with compatible imaging plus non-caseating granulomas and exclusion of mimics
  • Assess extent and organ involvement (lungs, heart, eyes, skin, liver, neuro, calcium)
  • Stage pulmonary disease and measure baseline lung function and symptoms
  • Identify high-risk involvement (cardiac, neuro, ocular, hypercalcaemia, renal) requiring treatment regardless of lung stage
  • Observe asymptomatic stage I-II disease with normal/stable physiology — many remit
  • Start oral corticosteroids for progressive/symptomatic pulmonary disease or major-organ disease
  • Add a steroid-sparing agent (e.g. methotrexate) for relapse or steroid dependence
  • Consider anti-TNF (infliximab) for refractory or neuro/cardiac disease
  • Monitor lung function, symptoms, calcium and steroid toxicity on a planned schedule
  • Treat fibrotic (stage IV) disease supportively; consider antifibrotics for progressive fibrosis and transplant for end-stage

Drugs & doses

Prednisolone 20-40 mg PO once daily, then slow taper to 5-10 mg maintenance over months
Methotrexate 10-15 mg PO once weekly with folic acid 5 mg weekly
Azathioprine 1-2 mg/kg PO once daily as alternative steroid-sparing agent
Infliximab 3-5 mg/kg IV at 0, 2, 6 weeks then every 4-8 weeks for refractory disease
Hydroxychloroquine 200-400 mg PO daily for cutaneous disease/hypercalcaemia

Disposition

Respiratory clinic; multidisciplinary input for cardiac/neuro/ocular involvement; transplant assessment for end-stage fibrosis.

Complications & pitfalls

  • Pulmonary fibrosis and respiratory failure
  • Pulmonary hypertension
  • Cardiac arrhythmia / sudden death
  • Hypercalcaemia and nephrolithiasis
  • Steroid and immunosuppressant toxicity

Exam pearls

  • Lofgren syndrome (erythema nodosum, bilateral hilar nodes, arthralgia) has an excellent prognosis and rarely needs steroids
  • Serum ACE is neither sensitive nor specific — do not use it to diagnose or monitor
  • Hypercalcaemia arises from macrophage 1-alpha-hydroxylase activity — advise sun/vitamin-D caution
  • Cardiac and neuro involvement warrant treatment even with minimal lung disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.